Berg Health
↗Framingham, Massachusetts, USA
Berg Health (now operating under BPGbio) is a clinical-stage, AI-powered biopharmaceutical company headquartered in Framingham, Massachusetts, that specializes in novel therapeutic discovery using its proprietary Interrogative Biology® platform. The company combines patient-derived biological data with Bayesian artificial intelligence algorithms to map disease mechanisms and identify novel drug targets across oncology, neurology, and rare diseases. Founded in 2006 with a mission to revolutionize drug discovery through a "back to biology" approach, Berg leverages one of the world's fastest supercomputers (Frontier at Oak Ridge National Laboratory) to process trillions of molecular data points and accelerate precision medicine development. The company was acquired by BPGbio (an investor consortium led by Phoenix Genesis) in February 2023 after raising approximately $400 million in previous rounds.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:AI-Powered Drug Discovery, Precision Oncology
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$5M (pre-acquisition)
Founded:2006
Ownership:private
Status:acquired
FUNDING
Stage:Late-stage/Acquisition
Total Raised:$400M+
Investors:Phoenix Genesis (lead investor through BPGbio), Alliance of Families Fighting Pancreatic Cancer, Department of Defense (partnership)
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:BPM31510 in Phase 1/2 for glioblastoma and Phase 2 for pancreatic cancer
Modalities:Small molecule, Topical formulations, Diagnostic biomarkers
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:BPGbio Inc.
Acquired By:BPGbio Inc. (2023-02-01)
Key Partnerships:Oak Ridge National Laboratory (Frontier supercomputer access for AI processing), Department of Defense (5-year research partnership, entered 2023), Stanford University (Interrogative Biology platform collaboration), University of Tennessee (research partnership), Icahn School of Medicine at Mount Sinai (neurodegenerative disease research, 2025), Multiple leading hospitals across Mexico (diagnostic validation)
COMPETITION
Position:Emerging Leader
Competitors:Exscientia (AI drug discovery, expanded AWS collaboration 2024), DeepMind/Google (AlphaFold protein folding, drug design), Atomwise (structure-based drug design with deep learning), Insilico Medicine, BenevolentAI, Recursion Pharma, insitro, GNS Healthcare +2 more
LEADERSHIP
Key Executives:
Niven R. Narain, Ph.D. - President & CEO, BPGbio (formerly President & CEO of Berg)
Carl Berg - Founder
Mitch Gray - Founder
Scientific Founders:Niven R. Narain, Ph.D.
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Berg Health. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.